Summary.-We have studied the cytotoxicity of bleomycin (4-10 u/kg/day for 6 days) given by continuous i.p. infusion (using an osmotic minipump) compared to daily i.p. bolus administration, against P388 leukaemic spleen colony-forming -units(LCFU -S). Continuous i.p. bleomycin at 8 u/kg/day caused a 0-5 log greater reduction of LCFU-S than did an identical dose given by intermittent bolus administration. The infusion minipump provided constant bleomycin plasma levels of 0-62 + 003 mu/ml and a total plasma AUC (area under the plasma decay curve) of 89-0 mu. h/ml for 6 days at 8 u/kg/day. Intermittent bolus bleomycin at 8 u.kg,/day had a terminal-phase plasma t1/2 of 15 min and a total 6-day plasma AUC of 90 8mu.h/ml. These pharmacokinetic data validate the osmotic minipump as a constant drug-delivery system, and suggest that the two administration schedules resulted in equal total bleomycin dosages. Although high peak bleomycin plasma levels (i.e. 32 mu/ml) were achieved with the intermittent bolus administration, continuous-infusion bleomycin's greater inhibition of LCFU-S was probably related to the drug's schedule-dependent cell-killing characteristics. The results of this study provide further rationale for the continuing use of infusion bleomycin schedules in cancer patients.
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BLEOMYCIN has proven effectiveness against several human cancers when administered either intermittently (i.v., i.m., s.c. or i.p.) or by continuous infusion (Prestayko & Crooke, 1979; Alberts et al., 1979) . There is some evidence that continuous i.v. infusion (C.i.v.) vs intermittent i.v. push (I.i.v.) bleomycin (when combined with mitomycin C and vincristine) is associated with similar response rates and less systemic toxicity in patients with squamous-cell cancer of the cervix (Baker et al., 1978) . More recently Sikic et al. (1978) (Sikic et al., 1978) . We have studied the effect of continuous i.p. (C.i.p.) vs intermittent i.p.
(I.i.p.) bleomycin against mouse leukaemia spleen colony growth, and have correlated the enhanced antileukaemic activity of C.i.p. with its more favourable plasma pharmacokinetics (Peng et al., 1979 Blood samples were centrifuged at 2,000 rev/min and 4°C for 10 min and the plasmas separated and immediately stored at -20°C. The bleomycin concentrations were determined using the antiserum and radioimmunoassay technique developed by Broughton & Strong (1976) . Bleomycin stability in the Alzet minipump was determined at 37°C for 7 days in saline.
Data analysis-Statistical analysis of the differences betwNeen LCFU dose-response (i.e., drug dose vs fraction of CFU surviving per femur) curves for the two different treatments used the analysis of covariance method (Snedecor & Cochran, 1979) . Bleomycin plasma concentrations vs time data were fitted to a single exponential equation using a nonlinear regressing computer programme (Metzler, 1969) . Bleomycin plasma half-lives and areas under the plasma disappearance curves (AUC) were calculated as previously described (Alberts et al., 1978) .
RESULTS
Bleomycin in 0 9%0 NaCi had 100% stability inside the osmotic minipumps for at least 6 days at 37°C. We were therefore able to use these minipumps to deliver a constant infusion of bleomycin for 6 days. caused an approximately 0 5 log greater reduction of LCFU than did I.i.p. bleomycin at doses of 6-10 u/kg/day (P < 001). The minipump provided constant bleomycin plasma levels of 062 + 0 03 mu/ml and a total AUC of 89-0 mu.h/ml for 6 days at 8 u/kg/day (Fig. 2) , whereas intermittent bolus bleomycin (8 u/kg/day) had a peak plasma level of 32 mu/ml (at 5 min), a terminal-phase plasma t1/2 of 1]5 min and a total 6-day AUC of 908 mu.h/ml. D1ISCUSSION We have shown that C.i.p. bleomycin caused a statistically greater inhibition of LCFU-S than did I.i.p. bleomycin at several points along the dose-response curve. These data and those of Sikic et al. (1978) showing C.s.c. bleomycin to be superior to I.s.c. bleomycin against Lewis lung carcinoma (Sikic et al., 1978) and to have less pulmonary toxicity (i.e., decreased content of lung collagen) strongly recommend continuous infusion as the route of choice for bleomycin administration. The study of Baker et al. (1978) in patients witl squamous-cell carcinoma of the cervix has shown that bleomycin given by C.i.v. along with mitomycin C and vincristine had as much antitumour activity and less systemic toxicity than when the drug was given Li.v. along wvith similar doses of the other 2 anticancer agents (Peng et al., 1979) .
Bleomycin appears to possess cell-cycle specificity in its antitumour effects (Barranco, 1979) . Like cytosine arabinoside (Skipper et al., 1967; Mellett, 1972) and other cell-cycle-specific agents, it may be necessary to maintain a minimal cytotoxic concentration of bleomycin while the tumour cell is traversing the S phase of the cell cycle in order to optimize cell kill. Our plasma disappearance data for bleomycin after C.i.p. administration shows that drug concentrations of greater than 0 6 mu/ml plasma are maintained for about 6 days. This is in contrast to the short periods (about 92 min) during which bleomycin plasma concentrations remain above 0-6 mu/ml after Li.p. administration. The improved tumour-cell kill associated with C.i.p. administration in this study and C.s.c. in the study of Sikic et al. (1978) can probably be explained by bleomycin's more favourable plasma kinetics after continuous infusion.
Future clinical-research studies using bleomycin in the treatment of the lymphomas and testicular, head and neck and lung cancers should be designed to evaluate the efficacy of the C.i.v. route. Using C.i.v. bleomycin it may be possible to maintain or improve on Li.v. bleomycin's antitumour activity while decreasing its pulmonary toxicity. Welfare and The Phi Beta Sci National Sorority, Lima, Ohio. We wish to thank Ruth Ann Lynn for her editing and typing of this manuscript.
